SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
A monoclonal antibody against HER-2 (trastuzumab) for metastatic breast cancer: a model-based cost-effectiveness analysis
4 references·5 citing·28 second hop
A monoclonal antibody against HER-2 (trastuzumab) for metastatic breast cancer: a model-based cost-effectiveness analysis (2005)A monoclonal antibody against HER-2 (tras…When does quality‐adjusting life‐years matter in cost‐effectiveness analysis? (2004)When does quality‐adjusting l…HER-2 Testing and Trastuzumab Therapy for Metastatic Breast Cancer: A Cost-Effectiveness Analysis (2004)HER-2 Testing and Trastuzumab…Health Economic Evaluations: The Special Case of End-Stage Renal Disease Treatment (2002)Health Economic Evaluations: …Cost-effectiveness analysis. (1993)Cost-effectiveness analysis.The Cost Burden of Trastuzumab and Bevacizumab Therapy for Solid Tumours in Canada (2008)The Cost Burden of Trastuzuma…Cost-effectiveness of HER2 testing and trastuzumab therapy for metastatic breast cancer (2008)Cost-effectiveness of HER2 te…Cost-effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a model-based analysis of the HERA and FinHer trial (2007)Cost-effectiveness of trastuz…Trastuzumab in adjuvant breast cancer therapy. A model based cost-effectiveness analysis (2006)Trastuzumab in adjuvant breas…An economic evaluation of Herceptin® in adjuvant setting: the Breast Cancer International Research Group 006 trial (2005)An economic evaluation of Her…Cost-Effectiveness in Health and Medicine (1996)Accounting for future costs in medical cost-effectiveness analysis (1997)Willingness to Pay for a Quality-adjusted Life Year (2000)Estimates of the lifetime costs of breast cancer treatment in Canada (2000)Cost Effectiveness of Adjuvant Trastuzumab in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer (2007)Decision Making in Health and Medicine: Integrating Evidence and Values (2001)What Is the Price of Life and Why Doesn't It Increase at the Rate of Inflation? (2003)A Cost-Effectiveness Analysis of Adjuvant Trastuzumab Regimens in Early HER2/neu–Positive Breast Cancer (2007)Cost‐effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2‐positive breast cancer (2007)Five‐Hundred Life‐Saving Interventions and Their Cost‐Effectiveness (1995)Measuring Preferences for Cost-Utility Analysis (2007)QALYs vs DALYs vs LYs gained: What are the differences, and what difference do they make for health care priority setting? (2009)Value-based medicine: concepts and application (2015)The Distinction Between Cost and Charges (1982)Recommendations of the Panel on Cost-Effectiveness in Health and Medicine (1996)Trastuzumab in early stage breast cancer: A cost-effectiveness analysis for Belgium (2008)The Markov Process in Medical Prognosis (1983)Methods for the Economic Evaluation of Health Care Programmes (2005)Short-course adjuvant trastuzumab therapy in early stage breast cancer in Finland: Cost-effectiveness and value of information analysis based on the 5-year follow-up results of the FinHer Trial (2011)Consolidated Health Economic Evaluation Reporting Standards (CHEERS)—Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force (2013)Health Economic Guidelines—Similarities, Differences and Some Implications (2001)Assessing the Real-World Cost-Effectiveness of Adjuvant Trastuzumab in HER-2/neu Positive Breast Cancer (2012)Recommendations for Reporting Cost-effectiveness Analyses (1996)Trends in Peer Learning (2005)Reprint—Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement (2009)Incremental cost-effectiveness ratios (ICERs): The silence of the lambda (2005)Medicare and Cost-Effectiveness Analysis (2005)Recommendations of the Advisory Committee on Immunization Practices (ACIP) (2008)
this work references cited by second hop

References

  • 1993Cost-effectiveness analysis.816 cited
  • 2002Health Economic Evaluations: The Special Case of End-Stage Renal Disease Treatment340 cited
  • 2004HER-2 Testing and Trastuzumab Therapy for Metastatic Breast Cancer: A Cost-Effectiveness Analysis230 cited
  • 2004When does quality‐adjusting life‐years matter in cost‐effectiveness analysis?114 cited

Cited by

  • 2007Cost-effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a model-based analysis of the HERA and FinHer trial55 cited
  • 2005An economic evaluation of Herceptin® in adjuvant setting: the Breast Cancer International Research Group 006 trial49 cited
  • 2006Trastuzumab in adjuvant breast cancer therapy. A model based cost-effectiveness analysis48 cited
  • 2008Cost-effectiveness of HER2 testing and trastuzumab therapy for metastatic breast cancer47 cited
  • 2008The Cost Burden of Trastuzumab and Bevacizumab Therapy for Solid Tumours in Canada47 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work